Created at	Source	Raw Value	Validated value
March 30, 2022, 3 p.m.	usa	Neutralizing antibody (NAb) responses (for Phase 1/2/3a and Phase 3c);Number of participants with a first occurrence of COVID-19;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to discontinuation;Percentage of participants reporting systemic events	Neutralizing antibody (NAb) responses (for Phase 1/2/3a and Phase 3c);Number of participants with a first occurrence of COVID-19;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to discontinuation;Percentage of participants reporting systemic events
Jan. 12, 2022, 9 a.m.	usa	Neutralizing antibody (NAb) responses (for Phase 1/2/3a and Phase 3c);Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to discontinuation;Percentage of participants reporting systemic events	Neutralizing antibody (NAb) responses (for Phase 1/2/3a and Phase 3c);Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to discontinuation;Percentage of participants reporting systemic events
Oct. 16, 2021, 3 p.m.	usa	Neutralizing antibody (NAb) responses (for Phase 1/2/3a);Number of participants with a first occurrence of COVID-19;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to discontinuation;Percentage of participants reporting systemic events	Neutralizing antibody (NAb) responses (for Phase 1/2/3a);Number of participants with a first occurrence of COVID-19;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to discontinuation;Percentage of participants reporting systemic events
Aug. 23, 2021, 7 p.m.	usa	Neutralizing antibody (NAb) responses (for Phase 1/2/3a);Number of participants with a first occurrence of COVID-19;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to disconsinuation;Percentage of participants reporting systemic events	Neutralizing antibody (NAb) responses (for Phase 1/2/3a);Number of participants with a first occurrence of COVID-19;Percentage of participants reporting adverse events;Percentage of participants reporting local reactions;Percentage of participants reporting serious adverse events, medically attended adverse events and adverse events leading to disconsinuation;Percentage of participants reporting systemic events